M.D. Anderson Cancer Center: Carcinoma, Transitional Cell trials

The registry lists 20 Carcinoma, Transitional Cell studies with M.D. Anderson Cancer Center as lead sponsor. 2 are open to participants now and 8 have results posted.

Phase 1 4Phase 2 15No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary TractRecruitingNCT07789119
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialRecruitingNCT04693377Not applicable
• Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial CancerTerminatedNCT04228042Phase 1/2Results posted
• Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT02923739Phase 2Results posted
• Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial CancerTerminatedNCT02693717Phase 2Results posted
• First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT01097746Phase 2Results posted
• Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the BladderCompletedNCT00963859Phase 2Results posted
• Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial CancerCompletedNCT00749892Phase 2Results posted
• Iressa and Taxotere Study in Patients With Metastatic Urothelial CancerTerminatedNCT00479089Phase 2Results posted
• Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney FunctionCompletedNCT00478361Phase 2Results posted
• A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial CarcinomaActive, not recruitingNCT05335941Phase 2
• A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the BladderActive, not recruitingNCT05137262Phase 2
• ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingNCT04953104Phase 2
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersActive, not recruitingNCT04388852Phase 1
• Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial CancerActive, not recruitingNCT03744793Phase 2
• Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02420847Phase 1/2
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseTerminatedNCT01552434Phase 1
• Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the UrotheliumActive, not recruitingNCT00756639Phase 2
• Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial TumorsActive, not recruitingNCT00567684Not applicable
• Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the UrotheliumCompletedNCT00080795Phase 2